Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd.
  6. News
  7. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD.

(4519)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Chugai Pharmaceutical : Discontinues Marketing of Photodynamic Diagnostic Agent 'ALAGLIO Divided Granules 1.5g'

05/10/2021 | 09:27am EDT

TOKYO - Chugai Pharmaceutical Co., Ltd. (Head office: Tokyo; President & CEO: Osamu Okuda; 'Chugai') and SBI Pharmaceuticals Co., Ltd. (Head office: Tokyo; Representative Director & President: Yoshitaka Kitao; 'SBI Pharma') announced that the companies decided to terminate the license agreement for the photodynamic diagnostic agent 'ALAGLIO Divided Granules 1.5g ('ALAGLIO')' and that Chugai will consequently discontinue marketing of the product.

Both companies entered into a license agreement for ALAGLIO on March 13, 2017 which granted Chugai exclusive marketing rights of ALAGLIO in Japan. SBI Pharma obtained regulatory approval for ALAGLIO on September 27, 2017 for the indication of diagnostic agent to visualize non-muscle invasive bladder cancer at the operation of its transurethral resection, and Chugai launched the product on December 19 after the product had been listed on the National Health Insurance reimbursement price list on November 22.

Chugai will discontinue marketing and information provision for ALAGLIO on May 31, 2021. SBI Pharma will announce how these activities will be conducted from June 1, 2021.

Chugai and SBI Pharma will corporate to accomplish a smooth transition and maintain promotion of proper use of the product during the transition period.

Trademarks used or mentioned in this release are protected by law.

Contact:

Corporate Communications Dept.

Chugai Pharmaceutical Co., Ltd.

press

Media Relations Group

Tel: +81-3-3273-0881

E-mail: pr@chugai-pharm.co.jp

Analysts/Investors

Investor Relations Group

Tel: +81-3-3273-0554

E-mail: ir@chugai-pharm.co.jp

SBI Pharmaceuticals Co., Ltd.

Marketing & Sales Dept.

(C) 2021 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
CHUGAI PHARMACEUTICAL CO., LTD. 1.30% 4435 End-of-day quote.-19.41%
ROCHE HOLDING AG -0.09% 341.7 Delayed Quote.10.68%
All news about CHUGAI PHARMACEUTICAL CO., LTD.
08:26aCHUGAI PHARMACEUTICAL  : Files New Drug Application in Japan for Faricimab, the ..
AQ
06:33aToshiba chair blames ex-CEO for firm's woes
RE
02:28aTOSHIBA  : chairman resists calls to resign, to bring in new directors
RE
01:39aOSAMU NAGAYAMA : Proxy adviser ISS continues recommendation against appointing T..
RE
12:02aToshiba to Appoint New Directors to Reform Corporate Governance
DJ
06/13Toshiba changes board nominees as two step down in deepening crisis
RE
06/12Toshiba board to hold emergency meeting on Sunday, sources say
RE
06/12Toshiba board to hold emergency meeting on Sunday, sources say
RE
06/12TOSHIBA  : directors to hold emergency meeting on board reassignments, sources s..
RE
06/11CHUGAI PHARMACEUTICAL  : Files New Drug Application in Japan for Faricimab, the ..
PU
More news
Financials
Sales 2021 829 B 7 530 M 7 530 M
Net income 2021 244 B 2 219 M 2 219 M
Net cash 2021 451 B 4 099 M 4 099 M
P/E ratio 2021 30,0x
Yield 2021 1,38%
Capitalization 7 291 B 66 289 M 66 231 M
EV / Sales 2021 8,25x
EV / Sales 2022 8,14x
Nbr of Employees 7 555
Free-Float 37,7%
Chart CHUGAI PHARMACEUTICAL CO., LTD.
Duration : Period :
Chugai Pharmaceutical Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 14
Average target price 4 777,69 JPY
Last Close Price 4 435,00 JPY
Spread / Highest target 39,8%
Spread / Average Target 7,73%
Spread / Lowest Target -12,1%
EPS Revisions
Managers and Directors
NameTitle
Tatsuro Kosaka Chairman & Chief Executive Officer
Osamu Okuda President, COO & Representative Director
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
CHUGAI PHARMACEUTICAL CO., LTD.-19.41%65 563
JOHNSON & JOHNSON5.08%434 405
ROCHE HOLDING AG10.68%328 612
PFIZER, INC.7.66%224 747
NOVARTIS AG-0.39%208 035
ABBVIE INC.7.70%203 857